BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Investigating the Advantages of a Bank account: A Complete Aide- Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- Vote in favor of the Top Vegetable for Senior
- Share your pick for the riding area that characterizes your surf undertakings!
- Fake new headlights rule steer Australian drivers astray
- Chinese mega embassy could bring security advantages, says No 10
- One of the best meteor showers of the year peaks at the worst possible time this week
- Journey Travel Objections for Your Next Experience
